"A new analysis published today in JAMA Cardiology has found that timely and broad adoption of Entresto sacubitrilvalsartan by all eligible heart failure patients with reduced ejection fraction HFrEF could prevent or postpone more than  deaths each year in the US alone. This analysis based on an application of the results of PARADIGMHF to published heart failure statistics is the first to quantify the possible impact of Entrestos potential benefit in reducing death. Heart failure is a chronic condition that contributes to more than  deaths in the US every year. About half of people with heart failure have HFrEF. This new analysis estimates that as many as  deaths in HFrEF patients annually could be prevented or postponed with optimal use of Entresto with sensitivity analyses demonstrating a range of  to . Further the study suggests that delaying routine use of Entresto in clinical practice could have a substantial negative effect on patients given the expected riskbenefit profile as it could result in failure to prevent tens of thousands of deaths. These findings demonstrate the significant survival benefits Entresto could offer to those living with HFrEF if patients in the group defined by the authors were given access to treatment. The study authors stated that nearly  of HFrEF patients  . million people  may be candidates for treatment with Entresto.   Heart failure is a lifethreatening condition and despite available medicines about half of patients diagnosed with heart failure die within  years. According to the study authors these findings may substantially impact the national health of the HFrEF population offering significant clinical benefit in preventing or postponing death when applied in clinical practice. This expert analysis adds to the already compelling case for the treatment of heart failure patients with reduced ejection fraction with Entresto said Fabrice Chouraqui president of Novartis Pharmaceuticals Corporation. In addition to survival benefits the study also recognizes other treatment effects of Entresto particularly in reducing HF hospitalizations. Coupled with the recent Class I recommendation the strongest endorsement in the focused update to the US HF Guideline these findings underscore the potential of Entresto as a standard therapy for chronic HFrEF patients. In a separate analysis published in the same issue of JAMA Cardiology researchers used data from the PARADIGMHF trial to model the health consequences and costeffectiveness of Entresto over a year time period. They compared Entresto to the ACEinhibitor enalapril and found Entresto was associated with more than a year longer average survival time and that it was costeffective compared to enalapril when these medications were used with other standard of care therapies. For every  patients treated with Entresto vs. enalapril potentially . HF hospital admissions could be averted per each year alive in the model. In addition Entresto increased life expectancy at an incremental costeffectiveness ratio consistent with other highvalue widely accepted cardiovascular interventions such as implantable cardioverter defibrillators ICDs and cholesterollowering statins before they became generic. About Heart Failure Heart failure is a debilitating and lifethreatening condition which impacts nearly  million Americans and is the leading cause of hospitalization among Americans over the age of . About half of people with heart failure have heart failure with reduced ejection fraction HFrEF. Reduced ejection fraction means the heart does not contract with enough force so less blood is pumped out. Heart failure presents a major and growing healtheconomic burden that currently exceeds  billion in the United States which accounts for both direct and indirect costs. About Entresto Entresto is a twiceaday medicine that reduces the strain on the failing heart. It does this by enhancing the protective neurohormonal systems Natriuretic Peptide system while simultaneously inhibiting the harmful effects of the overactive reninangiotensinaldosterone system RAAS. Other heart failure medicines only block the harmful effects of the overactive RAAS. Entresto contains the neprilysin inhibitor sacubitril and the angiotensin receptor blocker ARB valsartan. Entresto is indicated in the US to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure NYHA Class IIIV and reduced ejection fraction. Entresto is usually administered in conjunction with other heart failure therapies in place of an Angiotensin Converting Enzyme ACE inhibitor or an angiotensin II receptor blocker ARB. Entresto filmcoated tablets are available in three dosage strengths  mg  mg and  mg sacubitrilvalsartan. These doses are referred to as  mg  mg and  mg in the clinical trial literature including the New England Journal of Medicine publication of the results of PARADIGMHF. The target treatment dose of Entresto is  mg twice daily. Novartis is committed to providing patients with affordable access and resources through Entresto Central. For more information please call ENTRESTO or visit  http  Please visit http for Entresto full Prescribing Information. IMPORTANT SAFETY INFORMATION  Entresto can harm or cause death to an unborn baby. Patients should talk to their doctor about other ways to treat heart failure if they plan to become pregnant. If a patient gets pregnant while taking Entresto she should tell her doctor right away.  Patients are not to take Entresto if they are allergic to sacubitril or valsartan or any of the ingredients in Entresto have had an allergic reaction including swelling of the face lips tongue throat or trouble breathing while taking a type of medicine called angiotensinconverting enzyme ACE inhibitor or angiotensin II receptor blocker ARB or take an ACE inhibitor medicine. Patients are not to take Entresto for at least  hours before or after they take an ACE inhibitor medicine. Patients should talk with their doctor or pharmacist before taking Entresto if they are not sure if they take an ACE inhibitor medicine.  Patients are not to take Entresto if they have diabetes and take a medicine that contains aliskiren. Before they take Entresto patients should tell their doctor about all of their medical conditions including if they have kidney or liver problems are pregnant or plan to become pregnant are breastfeeding or plan to breastfeed. Patients should either take Entresto or breastfeed. They should not do both.  Patients should tell their doctor about all the medicines they take including prescription and overthecounter medicines vitamins and herbal supplements. They should especially tell their doctor if they take potassium supplements or a salt substitute nonsteroidal antiinflammatory drugs NSAIDs lithium or other medicines for high blood pressure or heart problems such as an ACE inhibitor ARB or aliskiren. Entresto may cause serious side effects including serious allergic reactions causing swelling of the face lips tongue and throat angioedema that may cause trouble breathing and death.  Patients are to get emergency medical help right away if they have symptoms of angioedema or trouble breathing. Patients are not to take Entresto again if they have had angioedema while taking Entresto.  People who are black or who have had angioedema may have a higher risk of having angioedema if they take Entresto. Entresto may cause low blood pressure hypotension. Patients are to call their doctor if they become dizzy or lightheaded or they develop extreme fatigue. Entresto may cause kidney problems or an increased amount of potassium in the blood.  The most common side effects were low blood pressure high potassium cough dizziness and kidney problems. Please see full Prescribing Information including Boxed WARNING available at http Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit  http or call FDA. Disclaimer  The foregoing release contains forwardlooking statements that can be identified by words such as could potential call for accelerate possible suggests expected may compelling endorsement potentially growing committed or similar terms or by express or implied discussions regarding potential new indications or labeling for Entresto or regarding potential future revenues from Entresto. You should not place undue reliance on these statements. Such forwardlooking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect actual results may vary materially from those set forth in the forwardlooking statements. There can be no guarantee that Entresto will be submitted or approved for any additional indications or labeling in any market or at any particular time. Nor can there be any guarantee that Entresto will be commercially successful in the future. In particular managements expectations regarding Entresto could be affected by among other things the uncertainties inherent in research and development including unexpected clinical trial results and additional analysis of existing clinical data unexpected regulatory actions or delays or government regulation generally the companys ability to obtain or maintain proprietary intellectual property protection general economic and industry conditions global trends toward health care cost containment including ongoing pricing pressures unexpected safety quality or manufacturing issues and other risks and factors referred to in Novartis AGs current Form F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forwardlooking statements contained in this press release as a result of new information future events or otherwise. About Novartis Novartis Pharmaceuticals Corporation researches develops manufactures and markets innovative medicines aimed at improving patients lives.  We offer a broad range of medicines for cancer cardiovascular disease endocrine disease inflammatory disease infectious disease neurological disease organ transplantation respiratory disease eye and ear care and skin conditions.  The companys mission is to improve peoples lives by pioneering novel healthcare solutions. Located in East Hanover NJ Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel Switzerland Novartis offers a diversified portfolio to best meet these needs innovative medicines eye care and costsaving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In  the Group achieved net sales of USD . billion while RD throughout the Group amounted to approximately USD . billion USD . billion excluding impairment and amortization charges. Novartis Group companies employ approximately  fulltimeequivalent associates. Novartis products are available in more than  countries around the world. For more information please visit http Novartis is on Twitter. Sign up to follow Novartis at httptwitter.comnovartis. References . Fonarow GC Hernandez AF Solomon SD et al. Potential Mortality Reduction with Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. JAMA Cardiol. . doi.jamacardio..  . Yancy CW Jessup M Bozkurt B Butler J Casey Jr DE Colvin MM Drazner MH Filippatos G Fonarow GC Givertz MM Hollenberg SM Lindenfeld J Masoudi FA McBride PE Peterson PN Stevenson LW Westlake C  ACCAHAHFSA Focused Update on New Pharmacological Therapy for Heart Failure An Update of the  ACCFAHA Guideline for the Management of Heart Failure httpscontent.onlinejacc.orgarticle.aspxarticleid Journal of the American College of Cardiology  doi .j.jacc....  . Gaziano TA Fonarow GC et al. CostEffectiveness Analysis of SacubitrilValsartan versus Enalapril in Heart Failure Patients with Reduced Ejection Fraction in the United States. JAMA Cardiol. . doi.jamacardio..  . Mozaffarian D Benjamin EJ Go AS et al. Heart Disease and Stroke Statistics Update A report from the American Heart Association. Circulation. ee. doi .CIR..  . Owan TE Hodge DO Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. .  . Roger VL Weston SA Redfield MM et al. Trends in heart failure incidence and survival communitybased population. JAMA.   . Levy D Kenchaiah S Larson MG et al. Long term trends in the incidence and survival with heart failure. N Engl J Med. .  . Weir LM Pfuntner A Maeda J et al. HCUP facts and figures statistics on hospitalbased care in the United States . Rockville MD Agency for Healthcare Research and Quality .  . Ejection Fraction Heart Failure Measurement. American Heart Association Website.http_UCM__Article.jsp. Published March  . Accessed March  .  . Heidenreich PA Albert NM Allen LA et al. Forecasting the impact of heart failure in the United States a policy statement from the American Heart Association. Circ Heart Fail. .  . Entresto Prescribing Information.  . Yancy CW Jessup M Bozkurt B et al.  ACCFAHA guideline for the management of heart failure A report of the American College of Cardiology FoundationAmerican Heart Association task force on practice guidelines. Circulation. ee. For Novartis multimedia content please visit  http For questions about the site or required registration please contact journalisthelpthenewsmarket.com mailtojournalisthelpthenewsmarket.com. SOURCE Novartis Pharmaceuticals Corporation Related Links http"